Rituximab

Enterome Highlights High Complete Response Rate in Clinical Study of EO2463 for Indolent Non-Hodgkin Lymphoma at ASCO 2024

Retrieved on: 
fredag, maj 24, 2024
Lenalidomide, Patient, CRS, Symantec Endpoint Protection, Rituximab, B-cell lymphoma, Poster, Safety, Inflammation, ASCO, Society, NHL, Immunotherapy, Annual general meeting, Pharmaceutical industry

PARIS, May 24, 2024 (GLOBE NEWSWIRE) -- Enterome, a clinical-stage company developing first-in-class immunomodulatory drugs for solid and liquid malignancies and inflammatory diseases based on its unique Mimicry platform, today announces updated immune-monitoring and clinical data from the ongoing EONHL1-20/SIDNEY trial evaluating EO2463 in monotherapy and in combination with lenalidomide and/or rituximab in indolent non-Hodgkin lymphoma (NHL). The results will be featured in a poster session on Monday, June 3rd, 2024, at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, USA.

Key Points: 
  • The results will be featured in a poster session on Monday, June 3rd, 2024, at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, USA.
  • “We are extremely encouraged by these results, which validate our OncoMimics™ approach to targeting liquid tumors,” said Dr. Jan Fagerberg, Chief Medical Officer of Enterome.
  • “In addition to the standalone activity seen with EO2463 during the first six weeks of treatment, the 78% complete response rate observed with the subsequent combination therapy supports our belief that EO2463 can significantly add to the patients’ care.
  • After 6 weeks of EO2463 monotherapy oral lenalidomide was added, and if no complete remission was achieved at week 19, rituximab was also included.

BRUKINSA® Data at ASCO Underscore Differentiated Clinical Profile for Treatment of CLL and SLL

Retrieved on: 
fredag, maj 24, 2024
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Patient, ASCEND, Chronic lymphocytic leukemia, Risk, Network, Clinical trial, University, Rituximab, PFS, Meta-analysis, Safety, Acalabrutinib, University of Washington, CLL, Blood, Abstract, Newsroom, ASCO, SLL, Associate, Lymphocytosis, BTK, Society, Hematology, BGNE, Survival, Annual general meeting, Pharmaceutical industry

“At this year’s ASCO, multiple presentations continue to add to our extensive body of evidence demonstrating BRUKINSA’s uniquely differentiated clinical profile,” Mehrdad Mobasher, M.D., M.P.H., Chief Medical Officer, Hematology at BeiGene.

Key Points: 
  • “At this year’s ASCO, multiple presentations continue to add to our extensive body of evidence demonstrating BRUKINSA’s uniquely differentiated clinical profile,” Mehrdad Mobasher, M.D., M.P.H., Chief Medical Officer, Hematology at BeiGene.
  • Results should be viewed in the context of analysis limitations and available randomized clinical trial data.
  • Data from this analysis provide important insights when evaluating the overall safety profile of individual BTKi treatments.
  • For additional information about BeiGene’s presence at the 2024 ASCO Annual Meeting, please visit our meeting hub in our newsroom .

Genmab to Showcase Data in Various Patient Populations to be Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting

Retrieved on: 
torsdag, maj 23, 2024
Science, Biotechnology, Research, Pharmaceutical, Oncology, General Health, Health, Clinical Trials, Lenalidomide, Patient, Abstract (summary), Lung cancer, Rituximab, Safety, ADC, Cancer, ASCO, Abstract, Society, Conjugation, Annual general meeting, Pharmaceutical industry

Data from the Phase 2 innovaTV 207 trial, evaluating tisotumab vedotin in pretreated patients with relapsed/metastatic head and neck squamous cell carcinoma will be presented during a rapid oral session.

Key Points: 
  • Data from the Phase 2 innovaTV 207 trial, evaluating tisotumab vedotin in pretreated patients with relapsed/metastatic head and neck squamous cell carcinoma will be presented during a rapid oral session.
  • Additionally, results from the Phase 3 innovaTV 301 trial evaluating tisotumab vedotin in patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy will be presented.
  • On Monday, June 3, at 9:00 AM CDT (10:00 AM EDT/4:00 PM CEST), Genmab will host a review of data presented at ASCO from its mid- to late-stage pipeline.
  • This meeting is not an official program of the ASCO Annual Meeting.

Indapta Therapeutics Awarded $4.5 Million by CPRIT to Advance Clinical Development of its Allogenic Natural Killer Cell Therapy

Retrieved on: 
tisdag, maj 21, 2024
Oncology, Health, Genetics, General Health, Clinical Trials, Pharmaceutical, Biotechnology, Genetic engineering, Interleukin, Patient, ADCC, Cytokine, NK, Clinical trial, Therapy, IND, Rituximab, Safety, Lymphoma, Multiple sclerosis, Cancer, Research, Multiple myeloma, Cytomegalovirus, CMV, Research institute, Cell, NKG2C

The $4.5 million grant will support Indapta’s ongoing clinical development of its lead product, IDP-023, for patients with advanced non-Hodgkin’s lymphoma and multiple myeloma.

Key Points: 
  • The $4.5 million grant will support Indapta’s ongoing clinical development of its lead product, IDP-023, for patients with advanced non-Hodgkin’s lymphoma and multiple myeloma.
  • “We greatly appreciate that CPRIT has recognized the promise of Indapta’s allogeneic g-NK cell therapy for the treatment of advanced cancer patients,” said Dr. Mark Frohlich, CEO of Indapta.
  • Indapta’s universal, allogeneic NK cell therapy platform consists of a potent subset of naturally occurring NK cells, known as “g minus” NK cells, or “g-NK” cells.
  • To generate IDP-023, Indapta preferentially expands g-NK cells from healthy donors, with low donor to donor variability.

Genmab to Present New and Updated Results From Multiple Clinical Trials Evaluating Epcoritamab Across Various B-Cell Malignancies at the 2024 European Hematology Association (EHA) Congress

Retrieved on: 
tisdag, maj 14, 2024
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Doxorubicin, Patient, Abstract (summary), Lymphoid leukemia, Prednisone, Rituximab, Safety, Congress, EHA, AbbVie, Cyclophosphamide, Abstract, DLBCL, Pharmaceutical industry

Genmab A/S (Nasdaq: GMAB) announced today that multiple abstracts evaluating epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously, will be presented at the 2024 European Hematology Association (EHA) Congress, being held in Madrid, Spain and virtually, June 13-16, 2024.

Key Points: 
  • Genmab A/S (Nasdaq: GMAB) announced today that multiple abstracts evaluating epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously, will be presented at the 2024 European Hematology Association (EHA) Congress, being held in Madrid, Spain and virtually, June 13-16, 2024.
  • Presentations will include data from clinical trials evaluating the safety and efficacy of epcoritamab as a monotherapy and in combination with standard-of-care or other novel therapies across multiple patient populations.
  • All abstracts accepted for presentation have been published and may be accessed online via the EHA Open Access Library .
  • “Together with AbbVie, we are committed to advancing and evolving the robust development program evaluating epcoritamab, as a monotherapy and in combination, across B-cell malignancies and settings.”
    The safety and efficacy of these investigational uses have not been established.

ADC Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates

Retrieved on: 
måndag, maj 6, 2024
PSMA, FDA, Net, University, Part, DLBCL, EDT, City, CRS, Safety, PIN, University of Miami, Pancreatic cancer, Infrared spectroscopy correlation table, Research, Hematology, Insurance, PR, MD, Growth, ICU, Rituximab, Follicular lymphoma, ADC, Patient, Therapeutic index, Sarcoma, S&M, Diffuse large B-cell lymphoma, NHL, Cytokine release syndrome, Marketing, IIT, Advertising, Therapy, NSCLC, Spacecraft, AXL, Lung cancer, Pharmaceutical industry

Sequential quarter-over-quarter growth in the first quarter of 2024 continued, with sales volume increasing in both community and academic settings.

Key Points: 
  • Sequential quarter-over-quarter growth in the first quarter of 2024 continued, with sales volume increasing in both community and academic settings.
  • Net product revenues were $17.8 million for the first quarter 2024, compared to $19.0 million for the first quarter 2023.
  • R&D expenses were $25.7 million for the first quarter 2024, compared to $38.4 million for the first quarter 2023.
  • ADC Therapeutics management will host a conference call and live audio webcast to discuss first quarter 2024 financial results and provide a company update today at 8:30 a.m. Eastern Time.

Genmab Announces Financial Results for the First Quarter of 2024

Retrieved on: 
torsdag, maj 2, 2024
USD, FDA, Pfizer, EDT, Priority review, AbbVie, Food, Risk, Annual report, Johnson & Johnson, DKK, Janssen, U.S. FDA, Risk management, Environment, Rituximab, Follicular lymphoma, Novartis, PDUFA, ADC, Patient, Acquisition, Interim, Lenalidomide, Daratumumab, Priority, BST, Pharmaceutical industry

Genmab is maintaining its 2024 financial guidance published on February 14, 2024.

Key Points: 
  • Genmab is maintaining its 2024 financial guidance published on February 14, 2024.
  • We expect to update our guidance no later than in connection with our second quarter 2024 earnings.
  • Genmab will hold a conference call to discuss the results for the first quarter of 2024 today, Thursday, May 2, at 6:00 pm CEST, 5:00 pm BST or 12:00 pm EDT.
  • Actual results or performance may differ materially from any future results or performance expressed or implied by such statements.

Enterome to Present Clinical Data on EO2463 in B-cell Lymphoma at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Retrieved on: 
torsdag, april 25, 2024
Safety, ClinicalTrials.gov, ASCO, Rituximab, Follicular lymphoma, Patient, Society, NHL, Inflammation, Annual general meeting, Lenalidomide, Pharmaceutical industry

PARIS, April 25, 2024 (GLOBE NEWSWIRE) -- Enterome, a clinical-stage company developing first-in-class immunomodulatory drugs for solid and liquid malignancies and inflammatory diseases based on its unique Mimicry platform, today announced that clinical data from the ongoing Phase 1/2 trial of EO2463 in monotherapy and in combination with lenalidomide and/or rituximab in indolent non-Hodgkin lymphoma (NHL) will be presented at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, to take place May 31 - June 4, in Chicago, Illinois.

Key Points: 
  • PARIS, April 25, 2024 (GLOBE NEWSWIRE) -- Enterome, a clinical-stage company developing first-in-class immunomodulatory drugs for solid and liquid malignancies and inflammatory diseases based on its unique Mimicry platform, today announced that clinical data from the ongoing Phase 1/2 trial of EO2463 in monotherapy and in combination with lenalidomide and/or rituximab in indolent non-Hodgkin lymphoma (NHL) will be presented at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, to take place May 31 - June 4, in Chicago, Illinois.
  • SIDNEY (EONHL1-20) is a Phase 1/2 multicenter, open-label, first-in-human study of EO2463 as monotherapy and in combination with lenalidomide and/or rituximab for the treatment of patients with indolent non-Hodgkin lymphoma (NHL).
  • The study aims to assess the safety, tolerability, immunogenicity, and preliminary efficacy of EO2463 monotherapy and combination therapy in approximately 60 patients with follicular lymphoma (FL) and marginal zone lymphoma (MZL).
  • For more information on the study, refer to Clinicaltrials.gov identifier: NCT04669171.

Pfizer Highlights Progress in Accelerating Breakthrough Cancer Medicines at ASCO 2024 Annual Meeting

Retrieved on: 
måndag, april 29, 2024
Research, FDA, Clinical Trials, Biotechnology, General Health, Pharmaceutical, Health, Science, Oncology, Other Science, PFS, Brentuximab vedotin, Triple-negative breast cancer, Lung cancer, MBC, ASCO, Lymphoma, PFE, Metastasis, ALK, Breast cancer, Learning, CRS, Food, Colorectal cancer, Abstract, RRMM, Rituximab, ADC, HR, CDK4, De novo, Spacecraft, DLBCL, Tucatinib, Anaplastic lymphoma kinase, Safety, Crizotinib, Pembrolizumab, Survival, EZH2, Pros, Inc., Neoplasm, Progression-free survival, Recurrence, PAL, Biologics license application, HRR, Hodgkin lymphoma, Patient, Society, Cyclin-dependent kinase 4, Cytokine release syndrome, Annual general meeting, APLS, PBC, Lenalidomide, B-cell lymphoma, Pharmaceutical industry

Pfizer Inc. (NYSE: PFE) highlights its progress in advancing new potential standards of care in Oncology at the 2024 American Society of Clinical Oncology (ASCO®) Annual Meeting, taking place May 31 to June 4 in Chicago.

Key Points: 
  • Pfizer Inc. (NYSE: PFE) highlights its progress in advancing new potential standards of care in Oncology at the 2024 American Society of Clinical Oncology (ASCO®) Annual Meeting, taking place May 31 to June 4 in Chicago.
  • “We are excited to participate in our first ASCO Annual Meeting following the creation of Pfizer’s new Oncology organization, where we will highlight our efforts to accelerate breakthrough medicines that help people with cancer live better and longer lives,” said Chris Boshoff, Chief Oncology Officer and Executive Vice President, Pfizer.
  • An oral presentation on extended duration of response from the Phase 3 MOUNTAINEER trial adds to the positive profile of TUKYSA in colorectal cancer.
  • Those interested in learning more can visit www.Pfizer.com/apls to access the summaries starting Friday, May 24.

Artiva Biotherapeutics Announces First Patient Dosed in Phase 1 Trial of AlloNK® Cell Therapy Candidate in Lupus Nephritis

Retrieved on: 
onsdag, april 17, 2024
Research, Genetics, Clinical Trials, Stem Cells, Biotechnology, Health, Pharmaceutical, Science, Oncology, Patient, Lupus nephritis, Nephritis, Safety, Lupus Research Alliance, Tissue, CD20, CD38, Lupus, Rituximab, Autoimmune disease, CD19, Cyclophosphamide, LN, NHL, Immune system, Clinical trial, Therapy, NK, Network, UC

AlloNK is a non-genetically modified, allogeneic, cryopreserved NK cell therapy candidate being developed to enhance the activity of B-cell targeting monoclonal antibodies to drive B-cell depletion.

Key Points: 
  • AlloNK is a non-genetically modified, allogeneic, cryopreserved NK cell therapy candidate being developed to enhance the activity of B-cell targeting monoclonal antibodies to drive B-cell depletion.
  • To our knowledge, this is the first time a patient has received an allogeneic NK cell therapy candidate in a U.S. clinical trial for treatment of an autoimmune disease.
  • Artiva is collaborating with Lupus Therapeutics, the clinical research affiliate of the Lupus Research Alliance, to support the evaluation of AlloNK for LN.
  • The Network, overseen by Lupus Therapeutics, is comprised of leading research centers throughout North America with the purpose of accelerating and optimizing lupus clinical trials.